Celon Pharma looking to debut on WSE in 2015
22:35
Pharmaceutical company Celon Pharma is considering an IPO next year to obtain PLN 150-200 million for clinical studies. “Our decision to enter the WSE will be made in autumn,” Maciej Wieczorek, CEO and owner of the firm, told the Polish Press Agency.
“To secure proof of concept for one drug, the company needs to conduct studies worth €20 million. The main focus of Celon Pharma is development and introduction of specialist generic drugs.”
“Inhalers produced by Celon cover about two-thirds of the reference drug market. We expect income for the sale of Salmex to reach PLN 50 million in 2014,” Wieczorek claimed. In 2013, the revenue of Celon Pharma reached about PLN 75 million, of which PLN 28 million came from sale of Salmex.
Wieczorek is looking to release the company’s asthma drug in France and the US. Patent protection on GSK’s Advair Diskus will end in 2016. Meanwhile, Celon plans to build a new production plant worth about €15-20 million. Celon Pharma is also a shareholder in the WSE-listed Mabion. Maciej Wieczorek is Mabion’s CEO.
